
Edgewise Therapeutics (EWTX) Stock Forecast & Price Target
Edgewise Therapeutics (EWTX) Analyst Ratings
Bulls say
Edgewise Therapeutics is attractive because the Servier transaction delivered $1.55 billion upfront and up to $2.65 billion total potential consideration, leaving the company with $1.7 billion in cash and runway into the early 2030s while it advances a focused cardiovascular strategy. The core bull case is EDG-7500, which in the 53-patient, 12-week Phase 2 CIRRUS-HCM Part D study showed meaningful improvements across hemodynamic, biomarker, symptom, and functional endpoints, including about 55% and 51% LVOT gradient reductions and a roughly 65% NT-proBNP decline, with no LVEF below 50% across more than 240 exposed individuals and over 700 echocardiograms. That combination of preserved systolic function, potential for lighter monitoring, and Phase 3 initiation guidance in YE26 supports differentiation versus existing cardiac myosin inhibitors, while EDG-15400 and EDG-003 add longer-dated pipeline optionality.
Bears say
Edgewise Therapeutics is a clinical-stage biopharmaceutical company with limited validated revenue-generating assets, so its value still depends on programs like Sevasemten and EDG-7500 successfully advancing through costly, uncertain development. The bear case is strengthened by regulatory risk around accelerated approval, possible REMS or echo monitoring requirements, and the need for larger, longer studies beyond the current 53-patient, 12-week dataset, which could delay commercialization and dilute differentiation. Competitive pressure from established CMIs such as mavacamten and aficamten, along with likely additional financing needs if the Servier transaction stalls or Phase 3 costs rise, further undermines the fundamental outlook.
This aggregate rating is based on analysts' research of Edgewise Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Edgewise Therapeutics (EWTX) Analyst Forecast & Price Prediction
Start investing in Edgewise Therapeutics (EWTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Edgewise Therapeutics (EWTX) Forecast
Edgewise Therapeutics (EWTX) Analyst Forecast & Price Prediction
Start investing in Edgewise Therapeutics (EWTX)
Order type
Buy in
Order amount
Est. shares
0 shares